{
    "nctId": "NCT03221231",
    "officialTitle": "N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms",
    "inclusionCriteria": "* Current DSM-IV diagnosis of cannabis dependence, \\>1 week detoxified and abstinent;\n* Able to provide written informed consent and to comply with study procedures.\n* Dutch speaking (Dutch as primary language).\n* Must be MALE\n* Must have minimum age of 18 Years\n* Must have maximum age of 45 Years",
    "exclusionCriteria": "* Currently dependent on any substance other than cannabis, alcohol or nicotine;\n* History of any major internal disease (including diabetes, cardiovascular disease, lung disease, liver or kidney disease);\n* An active or any history of neurological disorder, including but not limited to seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head trauma with prolonged loss of consciousness (\\>10 minutes), or migraine headaches;\n* An active or a history of a psychiatric disorder including, but not limited to, depression, schizophrenia, bipolar disorder, anxiety, or other psychiatric disorders;\n* Asthma;\n* Known hypersensitivity or allergy to n-acetylcysteine, or receiving chronic therapy with medication that could interact adversely with n-acetylcysteine within 30 days prior to randomization (i.e., nitroglycerin, ACE inhibitors or antihypertensive drugs, anti-coagulants);\n* Exclusion criteria for MRI: having metal in the body and/or having claustrophobia"
}